Arvinas: First-In-Human Data For Metastatic Castrate-Resistant Prostate Cancer (ASCO Preview)

The following article is exclusive to annual members and prepares reader’s for Arvinas’ upcoming first-in-human data at ASCO. Castrate-resistant prostate cancer has proven difficult-to-treat and patients are in crucial need of new therapeutics. PROTAC protein degraders may represent a major shift in biotechnology and Arvinas is in the lead. Arvinas’ lead agent, ARV-110, intends to […]
To access this post, you must purchase Prime Membership or Plus Membership.

This information is protected.

%d bloggers like this: